Finance

Beta
Lists
RCUS:NYSE
Arcus Biosciences Inc
$28.95
+0.49%
(+0.14) 1D
Jun 25, 9:45:22 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCUS...
Open
$28.68
High
$29.31
Low
$28.00
Mkt. cap
3.65B
Avg. vol.
1.21M
Volume
41.86K
52-wk high
$29.85
52-wk low
$7.91
EPS
-$3.18
Beta
0.85
Shares outstanding
125.77M
No. of employees
601
Open
$28.68
High
$29.31
Low
$28.00
Mkt. cap
3.65B
Avg. vol.
1.21M
Volume
41.86K
52-wk high
$29.85
52-wk low
$7.91
EPS
-$3.18
Beta
0.85
Shares outstanding
125.77M
No. of employees
601
News stories
From sources across the web
About Arcus Biosciences Inc
CEO-
Employees601
Founded2015
Headquarters-
SectorBiotechnology
Websitearcusbio.com
Analyst Ratings
Based on 9 analysts giving stock ratings to RCUS in the past 3 months
Strong Buy
Buy
7
Hold
2
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RCUS in the last 3 months.
Highest
Current $28.95
$47.00 (+62.35%)
Average
$36.75 (+26.94%)
Lowest
$22.00 (-24.01%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Unknown Analyst
Mizuho Securities
Buy
Maintained
$47.00
+62.3%
06/10/2026
Supawat Thongthip
Truist Financial
Buy
Maintained
-
-
06/04/2026
Charles Zhu
LifeSci Capital
Buy
Initiated
$46.00
+58.9%
06/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$32.00
+10.5%
06/03/2026
Gregory Renza
Truist Financial
Buy
Initiated
$35.00
+20.9%
05/18/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$22.00
-24%
05/11/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$34.00
+17.4%
05/07/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$41.00
+41.6%
04/22/2026
Jason Zemansky
Bank of America Securities
Hold
Maintained
$25.00
-13.6%
04/21/2026
Daina Graybosch
Leerink Partners
Buy
Maintained
$47.00
+62.3%
04/20/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$45.00
+55.4%
03/05/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
-
-
03/02/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
$30.00
+3.6%
02/27/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Downgraded
$23.00
-20.6%
02/12/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.02 / -$0.83
-23.26%miss
Revenue / Est. (USD)
17.00M / 29.48M
-42.34%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
160.00M
26.00M
33.00M
17.00M
Cost of goods sold
139.00M
141.00M
121.00M
122.00M
Cost of revenue
139.00M
141.00M
121.00M
122.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29.00M
27.00M
26.00M
29.00M
Operating expense
29.00M
27.00M
26.00M
29.00M
Total operating expenses
168.00M
168.00M
147.00M
151.00M
Operating income
-8.00M
-142.00M
-114.00M
-134.00M
Other non operating income
-
-
-
-
EBT including unusual items
-
-135.00M
-106.00M
-128.00M
EBT excluding unusual items
-
-135.00M
-106.00M
-128.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-
-135.00M
-106.00M
-128.00M
Net profit margin
-
-519.23%
-321.21%
-752.94%
Earnings per share
-
-1.27
-0.89
-1.02
Interest and investment income
10.00M
10.00M
10.00M
9.00M
Interest expense
-2.00M
-3.00M
-2.00M
-3.00M
Net interest expenses
8.00M
7.00M
8.00M
6.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.00M
-140.00M
-111.00M
-132.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer